НовостиBenzingaRodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56 Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56 Benzinga 2026.10.12 17:12 (GMT+0) Открыть на Benzinga Другие новости